etoposide + cisplatin + gemcitabine + doxorubicin + paclitaxel

This is a multi-agent chemotherapy regimen composed of five cytotoxic drugs—etoposide, cisplatin, gemcitabine, doxorubicin, and paclitaxel. Each component has a distinct mechanism of action targeting rapidly dividing cancer cells: - Etoposide is a topoisomerase II inhibitor that induces DNA strand breaks. - Cisplatin forms DNA crosslinks and inhibits DNA synthesis. - Gemcitabine is a nucleoside analog that inhibits DNA synthesis by incorporation into replicating DNA strands. - Doxorubicin intercalates into DNA and inhibits topoisomerase II, generating free radicals that damage cellular components. - Paclitaxel stabilizes microtubules and prevents their depolymerization during cell division. This combination would be considered highly intensive and experimental; while combinations of three (e.g., gemcitabine/etoposide/cisplatin) are documented in advanced cancers such as non-small-cell lung cancer or urothelial carcinoma[3][5][7][8], the addition of both doxorubicin and paclitaxel to this backbone is not standard in clinical practice due to overlapping toxicities. The regimen would be expected to have broad antitumor activity but also significant risk for myelosuppression, cardiotoxicity (from doxorubicin), neurotoxicity (from cisplatin/paclitaxel), mucositis, alopecia, nausea/vomiting, among others.